Skip to content
Boost Up Blog – Lifestyle
Author:
Immuneering Corporation
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 2, 2026
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
September 28, 2026
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 10, 2026
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
July 21, 2026
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
1
2
Next Page
→